February 17, 2020
1 min read
Save
CANDLE
Issue: February 2020
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Noninferiority of canagliflozin (Invokana, Janssen) vs. the sulfonylurea glimepiride in HF outcomes.
